Manufacturing
-
Stock via Getty Images
10 of our most read articles of 2024
The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.
By Meagan Parrish • Dec. 20, 2024 -
Scott Olson via Getty Images
Big Pharma’s new DTC play: partnering with digital health providers
The pharma giant is looking for another edge in the competitive weight loss market through DTC expansion.
By Amy Baxter • Dec. 18, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Stock via Getty Images
Trump’s tariffs could put more pressure on the U.S. to produce generic drugs. Are we ready?
The push to bring generic drug production back home has failed to reach a critical mass.
By Meagan Parrish • Dec. 6, 2024 -
Permission granted by Astellas
Q&AHow Astellas juggles the moving parts of cancer precision medicine development
While developing its first-in-class gastric cancer drug Vyloy, Astellas had to coordinate with another pharma giant to usher the precision med into the market.
By Michael Gibney • Dec. 5, 2024 -
Photo illustration: Industry Dive; Getty Images via Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Cell and Gene Therapy Pioneers
Leaders molding the cutting-edge cell and gene therapy field into tomorrow's cures.
By Michael Gibney • Oct. 30, 2024 -
hapabapa via Getty Images
Backlash builds against Novo’s Catalent takeover
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.
By Amy Baxter • Oct. 30, 2024 -
Buda Mendes via Getty Images
Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next?
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
By Alexandra Pecci • Oct. 23, 2024 -
Permission granted by Katelyn Jetelina
Q&A‘It’s been hard to watch.’ A noted epidemiologist talks H5N1 and the U.S.’s fragmented response.
Katelyn Jetelina, well known for her newsletter “Your Local Epidemiologist,” digs into the H5N1 outbreak, the public health response and what’s next for vaccinations.
By Alexandra Pecci • Oct. 9, 2024 -
hapabapa via Getty Images
Novo plans new plant as it races to meet drug demand
The new factory, which Novo is committing some $220 million to build, will supply raw materials for the company’s chronic disease medicines.
By Ned Pagliarulo • Aug. 19, 2024 -
Getty Images via Getty Images
Can robots break the cell therapy bottleneck?
A partnership between the cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could bring the manufacturing bottleneck under control, the CEOs said.
By Michael Gibney • May 29, 2024 -
stock via Getty Images
FTC request may signal trouble for Novo/Catalent deal
As Novo Nordisk aims to secure its manufacturing foothold for GLP-1s, regulators are digging for clues of anti-competitive behavior.
By Kelly Bilodeau • May 29, 2024 -
Stock via Getty Images
3 up-and-coming US biotech hotspots
These three U.S. cities are putting themselves on the biotech map as unsung hubs of the industry.
By Alexandra Pecci • May 21, 2024 -
Spencer Platt via Getty Images
As Lilly surges, headwinds against its weight loss drugs are growing
After missing analysts’ earnings expectations for Mounjaro sales in the first quarter due to overwhelming demand, Lilly is also dealing with a legal loss and incoming pricing questions from lawmakers.
By Amy Baxter • May 15, 2024 -
Anna Moneymaker via Getty Images
As drug shortages reach record highs, regulators float next steps
With many chemo and ADHD drugs stuck in stubborn shortages, several agencies are looking for new solutions to boost supplies.
By Kelly Bilodeau • May 6, 2024 -
Stock via Getty Images
FDA’s new diagnostic rules draw pharma criticism
Tests frequently used in clinical trials will soon be regulated like medical devices — with some exceptions.
By Amy Baxter • May 6, 2024 -
Scott Olson via Getty Images
As Lilly and BMS invest in manufacturing, demand for drugs still outweighs supply
From popular weight loss drugs to lifesaving cancer therapies, recent pharma deals show the industry is doubling down on manufacturing capacity to meet demand.
By Michael Gibney • April 25, 2024 -
Alex Wong/Getty Images via Getty Images
Q&AFormer U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake
A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.
By Michael Gibney • March 14, 2024 -
Anna Moneymaker via Getty Images
After ‘tragic’ bacterial outbreak, lawmakers press FDA to step up foreign inspections
Impatience to fix long-held challenges to overseas drug facility inspections is growing on Capitol Hill.
By Amy Baxter • March 1, 2024 -
Courtesy of Kite Pharma, Inc.
Kite’s next-gen CAR-T aims include quicker production and more disease targets
While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.
By Kelly Bilodeau • Feb. 20, 2024 -
Stock via Getty Images
3 questions hanging over the Novo-Catalent deal
As backlash builds for the recently announced matchup, critical questions remain over its impact.
By Kelly Bilodeau • Feb. 13, 2024 -
Permission granted by Precigen
Q&A // Red Jacket winners 2023Red Jacket: Helen Sabzevari, an immunotherapy pioneer
Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.
By Meagan Parrish • Oct. 27, 2023 -
Stock via Getty Images
3 recent FDA adcomm rejections — and why they matter
Decisions that could spell doom for drugs in development and already on the shelves.
By Meagan Parrish • Sept. 29, 2023 -
Permission granted by CSL Seqirus
Finding the right flu vaccine is hard. Getting people to take it is harder.
Experts have determined the strains of this year’s flu season — now the question is whether people are too fatigued by the pandemic to be immunized.
By Michael Gibney • Aug. 30, 2023 -
Stock via Getty Images
Drug shortages: The ‘fundamental problem’ that has pharma’s top regulator ‘fired up’
FDA Commissioner Robert Califf suggested larger reforms are needed to bolster the generic drug industry and prevent future medication shortages.
By Karissa Waddick • Aug. 25, 2023 -
Stock via Getty Images
Pharma’s rare disease rush
Biogen’s acquisition of Reata Pharmaceuticals is the latest in a string of high-dollar rare disease deals over the last few months. What does it mean for industry?
By Meagan Parrish , Karissa Waddick • Aug. 14, 2023
